financetom
Business
financetom
/
Business
/
Dev IT sells 5.45% stake in DevX at Rs 104 cr valuation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dev IT sells 5.45% stake in DevX at Rs 104 cr valuation
Dec 27, 2022 9:15 AM

Dev Information Technology Ltd, a technology solution provider delivering digital solutions leveraging Cloud, Automation & Data, has sold 5.45 percent of its equity holding in M/s. Dev Accelerator Pvt. Ltd. (DevX), a Managed Co-Working Space business, at a valuation of Rs 104 crore.

Share Market Live

NSE

Dev IT co-promoted ‘DevX’ in the year 2017 as a managed co-working space with 720 seats. As on September 30, 2022, DevX has 8,000 seats running at 79 percent capacity utilization levels. Since its inception, DevX has seen significant interest from investors to invest and participate in the growth of this business.

This secondary sale will bring down DEV IT’s shareholding in DevX from 41.26 percent to 35.81 percent. This will not only help unlock the valuation for shareholders of Dev IT but also help the company invest in new-age businesses like Blockchain, AI, and ML, amongst others, for the growth of its core business.

Jaimin Shah, Co-Founder Dev IT Limited, expressed, “Our secondary sale transaction in DevX shows the tremendous interest from investors in the business. This sale will allow us to not only unlock value for our shareholders but also provide significant cash flows in the company to expand new businesses in which we have been investing, namely Blockchain, and AI-ML, amongst others. Our company recently acquired a blockchain technology company to further its offering in this capability.”

Dev Information Technology (Dev IT) is a technology solutions provider delivering Digital Transformation, leveraging Cloud, Automation and Data Technologies.

First Published:Dec 27, 2022 6:15 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
New York City lawsuit against Exxon, BP, Shell over climate change dismissed
New York City lawsuit against Exxon, BP, Shell over climate change dismissed
Jan 15, 2025
* New York City says its 8.3 million residents were misled * Claims the companies engaged in 'greenwashing' rejected * City reviewing its legal options, seeks accountability (Adds Exxon and Shell comments in paragraphs 10-11) By Jonathan Stempel NEW YORK, Jan 15 (Reuters) - A judge has dismissed New York City's lawsuit seeking to hold Exxon Mobil ( XOM ),...
US says Toyota unit to plead guilty, pay over $1.6 bln to settle fraud scheme
US says Toyota unit to plead guilty, pay over $1.6 bln to settle fraud scheme
Jan 15, 2025
WASHINGTON, Jan 15 (Reuters) - A Toyota Motor Corp ( TM ) unit agreed to plead guilty and pay over $1.6 billion in a settlement with U.S. government agencies to settle violations related to an emissions fraud scheme, the U.S. Justice Department said in a statement on Wednesday. The Justice Department, FBI and Environmental Protection Agency, among other bodies, reached...
Novartis loses emergency bid to block Entresto generic in US
Novartis loses emergency bid to block Entresto generic in US
Jan 15, 2025
WASHINGTON - A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug Entresto. The decision by U.S. District Judge Dabney Friedrich clears a hurdle for MSN to introduce the first U.S. generic version of Switzerland-based Novartis' best-selling drug, which brought the company more than...
Novartis loses emergency bid to block Entresto generic in US
Novartis loses emergency bid to block Entresto generic in US
Jan 15, 2025
WASHINGTON, Jan 15 - A Washington, D.C. federal judge on Wednesday refused Novartis' eleventh-hour bid to block drugmaker MSN Pharmaceuticals from launching a generic version of Novartis' blockbuster heart-failure drug Entresto. The decision by U.S. District Judge Dabney Friedrich clears a hurdle for MSN to introduce the first U.S. generic version of Switzerland-based Novartis' best-selling drug, which brought the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved